Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
2025
2024
2023
2022
2021
2020
2019
-
May 29,2024
HuidaGene and Synthego Announce Licensing Agreement on Next-Generation Gene Editing Enzyme, hfCas12Max
Learn More
-
May 06,2024
HuidaGene Therapeutics Receives European Medicines Agency Orphan Designation for HG204 to Treat MECP2 Duplication Syndrome
Learn More
-
Apr 22,2024
HuidaGene Orally Presents Data Highlighting Strength of Ophthalmology Portfolio at the 2024 Association for Research in Visual and Ophthalmology Annual Meeting
Learn More
-
Apr 15,2024
HuidaGene Therapeutics to Open Up the First CRISPR MEDiCiNE European Conference
Learn More
-
Apr 15,2024
FDA Awards Orphan Drug and Rare Pediatric Disease Designations to the World’s First Cas13X RNA Base-editing Therapy for the Treatment of Congenital Hearing Loss
Learn More
-
Apr 08,2024
HuidaGene's Sixteen Abstracts Highlight the Strength of the Pipeline and Platform to Advance Genetic Medicines at the 2024 ASGCT Annual Meeting
Learn More
-
Jan 23,2024
HuidaGene Receives Orphan Drug Designation from FDA for HG302 for the Potential Treatment of Duchenne Muscular Dystrophy after Receiving Rare Pediatric Drug Designation
Learn More
-
Dec 19,2023
HuidaGene Announces Rare Pediatric Drug Designation Granted to HG302, A Novel CRISPR DNA-editing Therapy, for the Treatment of Duchenne Muscular Dystrophy
Learn More
-
Nov 03,2023
HuidaGene Therapeutics to Attend BIO-Europe Fall Conference in Munich for Actively Expanding Global Collaboration
Learn More